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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by joint swelling, joint tenderness, and destruction of
synovial joints, affecting more number of women than men. Sys-
temic inflammation in RA causes muscle wasting and compensa-
tory increase in the body fat, without a significant change in the
body weight (1-2). Several studies have indicated that patients with
RA have an abnormal body composition (3-4). In addition, our
previous study reported that sarcopenia was identified in 48.3%
and 54.0% of women and men with RA, respectively, which is more
frequent than the incidence in the Japanese elderly people (unpub-
lished). Sarcopenia is a condition that is characterized by progres-
sive and generalized loss of skeletal muscle mass and strength,
which causes a risk of adverse health outcomes, including physical
disability, poor quality of life (QOL), and death (5). Therefore, early
identification and treatment of sarcopenia in patients with RA are
important.
Owing to advances in the pharmacologic treatment of RA over
the past decade, the prognosis of patients with RA has improved
dramatically (6). Currently, patients with RA are treated with tradi-
tional anti -rheumatic drugs, nonsteroidal anti - inflammatory drugs,
steroids, biologic disease modified anti -rheumatic-drugs (biological
DMARDs), or Janus kinase (JAK) inhibitors.
Tofacitinib is the first JAK inhibitor approved for use to treat
patients with moderately to severely active RA who show inade-
quate response to or cannot tolerate methotrexate (MTX)(7). The
JAK enzymes (JAK1 and JAK3) have essential roles in the intra-
cellular signaling transduction of cytokines, leading to joint inflam-
mation and damage (8). By inhibition of cytokine signaling and
decreased inflammation, tofacitinib would improve the RA pathol-
ogy and patients’ condition.
BiologicalDMARDsare administered by subcutaneous or intra-
venous injections, which are sometimes limited or inconvenient,
whereas tofacitinib is administered orally, which relieves patients
from the burden of injections. It is recognized that tofacitinib
will be used more frequently or without biological DMARDs in the
future if sufficient experiences are accumulated through clinical
data.
Most therapeutic RA agents have been recently reported to
affect body composition, particularly decrease muscle and in-
crease body fat, and sarcopenic obesity has been identified in many
patients. In contrast, treatment with anti - tumor necrosis factor -α
(TNF-α) agent is known to maintain body composition (9-11). Be-
cause sarcopenia or decreased muscle mass is associated with bad
prognosis, considering the influence on body composition in se-
lecting RA therapeutic agents is important. JAK inhibition has been
reported to decrease lipolysis and increase body fat in mice (12). In
this study, we investigated whether tofacitinib has any effects on
body composition in mice and patients with RA.
MATERIALS AND METHODS
Animals : High fat fed C57BL/6 mice with Tofacitinib treatment
All animal experiments were approved by the institutional ani-
mal care and use committee at the University of Tokushima
Graduate School (Tokushima, Japan).
Female C57BL/6 mice were obtained from Japan SLC (Shizuoka,
Japan) and used at 8 weeks of age for experiments. Mice were
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housed in temperature (233) and humidity -controlled condi-
tions with a 12-h light/12-h dark cycle. Mice were given free
access to water and a high-fat diet (60% calories from fat ; Oriental
Yeast Ltd, Tokyo, Japan). They were divided into two groups :
control or treatment with tofacitinib. Body weight and food in-
take of each mouse were measured once a week.
Treatment with tofacitinib in C57BL/6 mice
Tofacitinib (LC Laboratories, Woburn, MA) was dissolved in a
sterile solution of 50% dimethyl sulfoxide, 40% water, and 10% poly-
ethylene glycol 300. Tofacitinib was administered 30 mg/kg/day
for 70 days via subcutaneous injection. The control group was ad-
ministered a corresponding volume of sterile solution without tofa-
citinib.
X-ray computed tomography scan
Trunk muscle and subcutaneous fat, visceral fat and % of body
fat were measured in mice under isoflurane anesthesia, using
LaTheta X-ray computed tomography (CT) scanner LCT-200
(HITACHI, Tokyo, Japan). Data were analyzed using LaTheta
software (HITACHI, Tokyo, Japan).
Oral glucose tolerance tests and insulin tolerance tests
Blood glucose levels were measured in tail vein blood samples
using a glucometer (Arklay, Kyoto, Japan). For oral glucose toler-
ance test (OGTT), blood glucose level was measured at 0, 15, 30, 60,
and 120 min after an oral glucose load (1.5g/kg), following an over-
night fast. For insulin tolerance test (ITT), blood glucose levels
were measured at 0, 15, 30, 60, and 120 min after an intraperitoneal
injection of insulin (0.75 U/kg), following a 6-h fast.
Subjects : female RA patients assessed by BIA
This study was approved by the ethical committee of Tokushima
University Hospital (Tokushima, Japan). Written informed consent
was obtained from each patient before enrollment. Pregnant women
and patients with pacemakers were excluded.
We included eight female patients aged 20 years and older, who
fulfilled the American College of Rheumatology/European League
Against Rheumatism classification criteria (13). The patients were
enrolled from June 2014 to December 2014 at Tokushima University
Hospital. The enrolled patients were divided into two groups :
treatment with tofacitinib or with other biological DMARDs (TNF-α
or IL-6 inhibitor). All patients were outpatients without other se-
vere disease such as diabetes and hypertension and asked about
disease duration and previous medication use including steroids.
RA disease activity score
Disease activity 28 (DAS28) was used to assess RA disease
activity. The DAS28 is a composite score derived from four meas-
ures, including the number of swollen and tender joints (out of the
28), pain score on the visual analog scale (VAS), and serum C-
reactive-protein (CRP) levels(14).
Body composition measurements by bioelectrical impedance
analysis
Bioelectrical impedance analysis (BIA) is a noninvasive and
widely used method for measuring body composition. In this
study, body composition was measured using InBody720 (InBody,
Tokyo, Japan) during the morning2 h after breakfast. The follow-
ing measurements were obtained : body weight, skeletal muscle
mass, and fat mass.
Statistical analysis
Data were expressed as meansstandard deviation (SD). Values
were analyzed using unpaired Student t test or paired t - test. A p
value of0.05 was considered statistically significant. All analyses
were performed using Statcel Ver.3.0 (OMS Publishing, Saitama,
Japan).
RESULTS
Effect of tofacitinib on body composition in mice
We first examined body weight and body composition by using X-
ray CT scan to study the effect of tofacitinib on body composi-
tion in C57BL/6 mice treated with tofacitinib. Treatment with
tofacitinib did not affect body weight and body composition (data
not shown). Based on this result, tofacitinib administration to normal
mice might not affect body composition. We subsequently used
C57BL/6 mice fed with a high-fat diet for 4 weeks to cause weak
inflammation. Figure 1A shows that treatment with tofacitinib did
not affect body weight without affecting food intake. In addition,
Figure 1 Treatment with tofacitinib did not affect body
weight and body composition.
Mice were fed with a high- fat diet and were treated with 30 mg/kg/day
tofacitinib or vehicle for 70 days (tofacitinib, n=9 ; vehicle, n=7). Body
weight was measured weekly (A). Body composition was assessed using
computed tomography, with the trunk muscle content (g/body weight ;
B), subcutaneous fat content (g/body weight ; C), visceral fat content (g/
body weight ; D), and the relative body fat content (E) quantified.
Values are presented as meanstandard deviation (A-E). Control :
vehicle - treated group (open squares in glaph A) ; tofacitinib : tofacitinib -
treated group (closed squares). Control : vehicle - treated group (open
columns in glaph B-E) ; tofacitinib : tofacitinib - treated group (closed
columns).
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no differences of %volume were found in the trunk muscle and
subcutaneous fat or visceral fat between the two groups (Fig 1B-
E). We also examined OGTT and ITT. Treatment with tofacitinib
did not affect glucose and insulin tolerance (Figure 2A and 2B).
Effect of tofacitinib on body composition in patients with RA
We subsequently compared the body composition in female pa-
tients with RA treated with tofacitinib and those treated with other
biological DMARDs. The characteristics of patients are listed in
Tables 1 and 2.
We evaluated the body composition before and 3 months after
treatment initiation. Treatment with biological DMARDs did not
affect body weight, skeletal muscle mass, and body fat mass
(Figure 3A-C). By contrast, the body weight of patients treated
with tofacitinib tended to increase (p=0.06). Although treatment
with tofacitinib did not affect muscle mass, body fat mass was sig-
nificantly increased (p0.05). The DAS-28 scores improved in
both groups (Fig 3D).
DISCUSSION
In this study, we investigated the effect of tofacitinib on body
composition in mice fed with a high-fat diet and patients with RA.
Our results show that tofacitinib did not affect body weight and
body composition in mice treated withtofacitinib. Previous studies
have suggested that JAK-STAT signaling pathways play important
roles in adipose tissue function (15-16). Shi et al. reported that
adipocyte-specific deficiency of JAK2 in mice impairs lipolysis and
increases body weight (12). However, our results in mice treated
with tofacitinib did not show weight gain and increased fat mass.
Figure 2 Treatment with tofacitinib did not affect glucose
and insulin tolerance.
Glucose (A) and insulin (B) tolerance tests were performed in mice fed
with high- fat diet after an overnight (16 h) (A) or 6 -h (B) fast. Mice were
administered an oral dose of 1.5 g/kg glucose (A) or 0.75 U/kg insulin by
intraperitoneal injection (B). Blood glucose was measured at the indi-
cated times. Glucose utilization and insulin sensitivity were determined
from the area under the curve (AUC ; inset). Open squares : vehicle -
treated group ; closed squares : tofacitinib - treated groups. Values are
presented as meansstandard deviation.
Table. 1
Characteristics of participants and disease
Biological DMARDs
(n=4)
Tofacitinib
(n=4) P value
Age (years) 57.014.7 55.319.5 0.891
Sex : Male : Female 0 : 4 0 : 4
Disease duration (years) 5.810.8 8.56.6 0.679
Steroids dairy dose (mg) 1.11.4 3.35.3 0.485
DAS28 CRP 5.00.7 5.10.8 0.742
Energy intake (kcal/kgBW/day) 30.77.9 35.96.1 0.337
Data is presented as meanstandard deviation (SD). The two groups
compared using unpaired Student’s t test.
Table. 2
Difference of body composition data between biological DMARDs and
Tofacitinib groups
Biological DMARDs
(n=4)
Tofacitinib
(n=4) P value
Body mass index (kg/m2) 24.45.1 24.04.9 0.924
Body fat mass (%) 32.98.0 32.34.8 0.906
Skeletal muscle mass(kg) 22.33.3 20.44.0 0.490
Skeletal muscle index (kg/m2) 5.00.7 6.41.1 0.918
Body cell mass (kg) 26.73.6 24.64.4 0.500
Edema (%, n) 0 (0) 25 (1) 0.500
Data is presented as meanstandard deviation (SD) or proportions (%).
The two groups compared using unpaired Student’s t test.
Figure 3 Treatment with biological DMARDs did not affect
body composition, whereas treatment with tofacitinib sig-
nificantly increased body fat mass.
We evaluated body composition 3 months after treatment initiation in
patients treated with biological DMARDs or tofacitinib (n=4 per group).
Body mass index (A), skeletal muscle mass (B), and body fat mass (C)
were measured using bioelectrical impedance analysis (BIA). Disease
activity score was also caluculated (D). Values are presented as means
standard deviation. Open bars : before treatment, closed bars : 3 months
after treatment initiation.*P0.05,**P0.01 3 months after treatment
initiation vs. before treatment.
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The JAK-STAT pathway might occur in most cells and mediate the
action of numerous cytokines, growth factors, energy expenditure,
and cellular differentiation (17). Tofacitinib inhibits JAK enzyme,
JAK1, JAK2, and JAK3, and shuts down the signaling of inflamma-
tory cytokines by binding to cytokine receptors on the surface of
immune cells, which improves the pathology of RA. However, the
amount of tofacitinib affecting the JAK signal of adipose tissues is
still unclear. Because previous studies only used knockout mice
that target JAK-STAT activators, the mechanism of JAK inhibition
caused tofacitinib does not involve lipolysis and body fat accumula-
tion i.e., treatment with tofacitinib may not act as strongly as in the
knockout mice.
In the present study, patients with RA had a higher percentage of
body fat, which was comparable among patients treated with bio-
logical DMARDs (32.98.0%) and those with tofacitinib (32.3
4.8%). A variety of factors are involved in the increase of fat, in-
cluding inflammatory cytokines, glucocorticoid use, and de-
creased physical activity due to pain. Indeed, our patients with
tofacitinib used about 3- fold steroids compared to patients with
DMARDs. This might affect on body fat percent. Several reports
have demonstrated that anti -TNF-α therapy for RA has not been
effective in obese patients (5-6). Jhun et al. also demonstrated that
obesity aggravates joint inflammation in a collagen- induced arthritis
model (7). Thus, a higher percentage of body fat increases RA
severity. The suppression of the appropriate disease activity may
be the most important strategy to treat metabolic abnormalities.
In the patients treated with tofacitinib, the body weight tended to
increase, and fat mass significantly increased. Various factors may
have contributed to body weight gain and fat increase. Because
tofacitinib can be taken orally, which is safer than subcutaneous
injection, it is suitable for use by elderly people. Although no signifi-
cant difference was found in age between the biological DMARDs
and tofacitinib groups, only the tofacitinib group included elderly
people over 75 years. Furthermore, patients with high use of ster-
oids were also included in the tofacitinib group. Steroid use is very
common factor to increase body fat. The large variation because of
the small sample size is the limitation of this study. Further in-
vestigation is needed with a large sample size.
In addition, the DAS in both groups of patients improved after
treatment initiation. Because of the improved symptoms, dietary
intake and physical activity may have changed, possibly leading to
weight change. The effect of biological DMARDs on body composi-
tion has also been reported. Treatment with anti -TNF has been re-
ported to not change body composition in the short term (after 12
weeks of therapy) (8-9). Biological DMARDs have been reported
to preserve fat - free mass. Our results were consistent with the
previous study. We also showed that tofacitinib maintained fat - free
mass similar to biological DMARDs. However, regarding fat mass,
some report showed that anti -TNF therapy increases body fat
mass in early RA (10). Our results were not consistent with this
point. Examination of the fat of each part, such as trunk fat, is impor-
tant.
In this study, different results were occurred in mice and pa-
tients. One of reasons might because of our mice model. We did not
find any change of body fat when we use mele mice with normal
chow, we have tried touse female with high fat diet to induce weak
inflammation. It might be better to use some RA model mice
such as SKG mice. Also, as we described above, there were some
variations between patients, especially steroid use, we further need
to see the effect of tofacitinib on body composition.
Taking together, there is still possibility that tofacitinib may im-
prove body composition.
However, whether tofacitinib is superior to methotrexate in the
long-term treatment of RA remains unknown. Additional larger
studies are needed to explore this possibility.
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